

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Ozagrel sodium

July 17, 2019

Therapeutic category

Circulatory organ agents-miscellaneous

Miscellaneous metabolism agents-miscellaneous

Non-proprietary name

Ozagrel sodium

Safety measure

Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions): Revised language is underlined.

Current	Revision
<p>Contraindications</p> <p>Patients with cerebral embolism</p>	<p>Contraindications</p> <p><u>Patients with major infarction accompanied by serious impairment of consciousness</u>, patients with cerebral embolism</p>
<p>Relative Contraindications</p> <p><u>Patients with major infarction accompanied by serious impairment of consciousness</u></p>	<p>Relative Contraindications</p> <p>(deleted)</p>

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
 E-mail: safety.info@pmda.go.jp